Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Orlistat and the risk of acute liver injury

This week's issue of the British Medical Journal investigates the association between orlistat and the risk of acute liver injury.

News image

Dr Ian Douglas and colleagues from the United Kingdom measured the association between orlistat and acute liver injury.

The team performed a self controlled case series study in a population based primary care setting.

The research team evaluated 94,695 patients receiving orlistat, who were registered in the UK Clinical Practice Research Datalink and linked with Hospital Episode Statistics data between 1999 and 2011.

The team's main outcome measure included the relative incidence of acute liver injury comparing periods when patients were receiving orlistat with periods of non-usage.

The incidence remained raised during the first 30 days of treatment
British Medical Journal

Among 94,695 patients who received orlistat, 988 cases of acute liver injury were identified, with 335 confirmed as definite cases and 653 as probable cases.

For all cases an increased incidence of liver injury was detected during the 90 day period before orlistat was first started, with an incidence rate ratio of 1.50.

The incidence remained raised during the first 30 days of treatment, before returning to baseline levels with prolonged treatment.

When the risk during the first 90 days of treatment was compared with the 90 days preceding first treatment, the incidence of liver injury was not increased.

The team showed no evidence of an increased risk of liver injury during treatment.

Dr Douglas' team concludes, "The incidence of acute liver injury was higher in the periods both immediately before and immediately after the start of orlistat treatment."

"This suggests that the observed increased risks of liver injury linked to the start of treatment may reflect changes in health status associated with the decision to begin treatment rather than any causal effect of the drug."

BMJ 2013; 346: f1936
06 May 2013

Go to top of page Email this page Email this page to a colleague

 24 July 2014

Advanced search
 24 July 2014 
Diagnostic tool for obscure-overt GI bleeding
 24 July 2014 
Statin use and Barrett’s esophagus
 24 July 2014 
Atopy and functional GI disorders
 23 July 2014 
Sofosbuvir and ribavirin for Hep C
 23 July 2014 
Early corticosteroids after the diagnosis of ulcerative colitis
 23 July 2014 
C-section and IBD risk
 22 July 2014 
Thromboembolism in IBD
 22 July 2014 
Alcohol and colorectal adenoma risk
 22 July 2014 
Cognitive behavioral therapy in IBS
 21 July 2014 
Stents to prevent post-ERCP pancreatitis
 21 July 2014 
Psychometric validation of IBS symptom severity
 21 July 2014 
Mortality in IBD
 18 July 2014 
Treatment of enteropancreatic neuroendocrine tumors
 18 July 2014 
Ulcer complications and dyspeptic symptoms
 18 July 2014 
ERCP with overtube-assisted enteroscopy
 17 July 2014 
Treatment of H. pylori
 17 July 2014 
Ultrasound for diagnosis of gastric varices
 17 July 2014 
Small intestinal permeability in diarrhea predominant IBS
 16 July 2014 
Mortality after colectomy in IBD
 16 July 2014 
Esophageal cancer missed at endoscopy
 16 July 2014 
Screening for Hepatitis B
 15 July 2014 
Diagnosing diverticulitis
 15 July 2014 
Variation in management decisions for colorectal cancer
 15 July 2014 
Muscle cramps in cirrhosis
 14 July 2014 
Predicting the course of ulcerative colitis
 14 July 2014 
Choice in colorectal cancer screening tests
 14 July 2014 
Adhesions in abdominal surgery
 11 July 2014 
Temporal evolution of antidrug antibodies in IBD
 11 July 2014 
Atopy and functional gastrointestinal disorders
 11 July 2014 
Fecal microbiota transplant for C. diff
 10 July 2014 
Acid-suppressive medications and cancer risk in Barrett's
 10 July 2014 
Personalized medicine in the management of IBD
 10 July 2014 
Pregnancy outcome in anti-TNF treated women with IBD
 09 July 2014 
Quality of care provided to patients with varices
 09 July 2014 
Eosinophilic esophagitis and celiac disease
 09 July 2014 
Diagnosis and management of adult celiac disease
 08 July 2014 
Screening for Hep B
 08 July 2014 
NSAID-induced small intestinal injury
 08 July 2014 
Drug-induced liver injury
 07 July 2014 
Obesity and complications after lapaproscopic colorectal surgery
 07 July 2014 
Everolimus and advanced hepatocellular carcinoma
 07 July 2014 
Pediatric celiac disease risk factors
 04 July 2014 
Day-case vs inpatient laparoscopic fundoplication
 04 July 2014 
Alcohol assessment in liver transplant
 04 July 2014 
Clinical competence in colorectal cancer surgery
 03 July 2014 
Predicting acute liver failure in drug-induced liver injury
 03 July 2014 
Cognitive dysfunction impairs quality of life after liver transplant
 03 July 2014 
NOTES for colon resections
 02 July 2014 
Routine colonoscopy for uncomplicated diverticulitis
 02 July 2014 
Risk of stroke in ulcerative colitis
 02 July 2014 
Hemodialysis during liver transplant
 01 July 2014 
Outcomes for pregnant women with primary biliary cirrhosis
 01 July 2014 
Liver-prognosis assessment in Hep C
 01 July 2014 
Mortality from biliary diseases requiring ERCP
 30 June 2014 
Combination therapy for eradication of Helicobacter pylori
 30 June 2014 
Drug-induced liver injury
 30 June 2014 
Surrogate for adenoma detection rate
 27 June 2014 
Infliximab and luminal pediatric Crohn's
 27 June 2014 
Colonoscopy surveillance intervals
 27 June 2014 
Endoscopy protocol for serrated polyposis syndrome

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us